Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D4LY | ISIN: US00773J2024 | Ticker-Symbol: 3920
Frankfurt
31.03.25
08:00 Uhr
16,100 Euro
-0,100
-0,62 %
1-Jahres-Chart
SPYRE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
SPYRE THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
14,70015,10022:00

Aktuelle News zur SPYRE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrBTIG maintains Spyre stock Buy rating, $70 target1
DoSpyre Therapeutics, Inc.: Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody50Preclinical data demonstrates that SPY003 is highly potent and has potential forquarterly or biannual dosing, suggesting opportunity for improved efficacy andconvenience...
► Artikel lesen
DoSpyre Therapeutics (NASDAQ:SYRE) Reaches New 1-Year Low - Here's Why1
18.03.Wolfe Research initiates Spyre stock with Outperform rating1
12.03.Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up - Should You Buy?1
SPYRE THERAPEUTICS Aktie jetzt für 0€ handeln
27.02.Spyre Therapeutics GAAP EPS of -$0.81 beats by $0.211
27.02.Spyre Therapeutics, Inc.: Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update333Reported positive interim pharmacokinetic ("PK") and safety data in Phase 1 trial of SPY001 in November 2024 and strengthened the balance sheet with a $230 million...
► Artikel lesen
27.02.Spyre Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
27.02.Spyre Therapeutics, Inc. - 8-K, Current Report-
13.01.Spyre Therapeutics, Inc.: Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts122Phase 1 interim results expected for SPY002, two distinct extended half-life TL1A antibodies, in 2Q2025 Phase 1 interim results expected for SPY003, an extended...
► Artikel lesen
13.01.Spyre Therapeutics, Inc. - 8-K, Current Report-
02.12.24Spyre begins Phase 1 trials for new IBD treatments2
02.12.24Spyre startet Phase-1-Studien für neue CED-Behandlungen3
02.12.24Spyre Therapeutics, Inc.: Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies235Spyre is concurrently advancing two anti-TL1A molecules into first-in-human studies Preclinical data for both SPY002 molecules demonstrate picomolar potency and...
► Artikel lesen
19.11.24Spyre Therapeutics announces pricing of $200 million public offering of common stock8
19.11.24Spyre Therapeutics Prices Public Offering Of About 7.28 Mln Shares At $27.50/shr-
18.11.24Spyre Therapeutics startet öffentliches Angebot über 200 Millionen US-Dollar1
18.11.24Spyre Therapeutics launches $200 million public offering1
18.11.24Spyre Therapeutics, Inc. - 10-Q/A, Quarterly Report-
18.11.24Spyre Therapeutics, Inc. - 10-K/A, Annual Report-
Seite:  Weiter >>
48 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1